European Commission grants marketing approval for BAH’s Neptra ear drops

Bayer Animal Health’s (BAH) state-of-the-art Neptra ear drops, for the treatment of acute exacerbations of recurrent otitis or acute canine otitis externa in dogs, have been granted marketing approval by the European Commission. The single dose ear drops, which contain mometasone furoate, florfenicol and terbinafine hydrochloride, will be made available early in the New Year.

Mario Andreoli, BAH’s Head of Marketing, stated: “Neptra offers a key advantage unlike competing products, it requires just one dose administered by the veterinarian in the practice. No at home applications by the dog owner are required. The treatment stays in the hands of the veterinarian and therefore, allows full control over compliance.”